Update on pharmacotherapy guidelines for the treatment of neuropathic pain
Neuropathic pain is a common problem in our society affecting nearly 1.5% of the US population. There currently are five medications approved by the US Food and Drug Administration (FDA) for the treatment of neuropathic pain, which include gabapentin, pregabalin, duloxetine, 5% lidocaine patch, and...
Gespeichert in:
| Veröffentlicht in: | Current pain and headache reports 2006-06, Vol.10 (3), p.185-190 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 190 |
|---|---|
| container_issue | 3 |
| container_start_page | 185 |
| container_title | Current pain and headache reports |
| container_volume | 10 |
| creator | Dobecki, Douglas A Schocket, Sanford M Wallace, Mark S |
| description | Neuropathic pain is a common problem in our society affecting nearly 1.5% of the US population. There currently are five medications approved by the US Food and Drug Administration (FDA) for the treatment of neuropathic pain, which include gabapentin, pregabalin, duloxetine, 5% lidocaine patch, and carbamazepine. Other agents with proven efficacy in multiple randomized, placebo-controlled trials include opioids, tricyclic antidepressants, venlafaxine, and tramadol. All of these agents, both FDA-approved and off-label, have been recommended as first-line treatments for neuropathic pain. This article discusses these agents in detail as they relate to the treatment of neuropathic pain. |
| doi_str_mv | 10.1007/s11916-006-0044-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68404728</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68404728</sourcerecordid><originalsourceid>FETCH-LOGICAL-c267t-8b858f16f5587e257547d858aa2c2fba2eb1e0544bc3ca4199bad003abb4a5753</originalsourceid><addsrcrecordid>eNpdkE1LxDAQhoMo7rr6A7xIQPBWzVeb9CiLnyx4cc9hkqZul7apSXrYf2_XXRA8DDO8PDMMD0LXlNxTQuRDpLSkRUbIvoTIyhM0pzkXGSeKnv7ONOOC8xm6iHFLCCNK0XM0o0pKlUs2R-_roYLksO_xsIHQgfVp4wIMO_w1NpVrm95FXPuApxin4CB1rk_Y17h3Y_ADpE1j8QBNf4nOamijuzr2BVo_P30uX7PVx8vb8nGVWVbIlCmjclXTos5zJR3LZS5kNUUAzLLaAHOGOpILYSy3IGhZGqgI4WCMgInmC3R3uDsE_z26mHTXROvaFnrnx6gLJYiQTE3g7T9w68fQT79pJkghRFFSMVH0QNngYwyu1kNoOgg7TYnea9YHzXrSrPeadTnt3Bwvj6Zz1d_G0Sv_ARapd_Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2406446914</pqid></control><display><type>article</type><title>Update on pharmacotherapy guidelines for the treatment of neuropathic pain</title><source>MEDLINE</source><source>2022 ECC(Springer)</source><creator>Dobecki, Douglas A ; Schocket, Sanford M ; Wallace, Mark S</creator><creatorcontrib>Dobecki, Douglas A ; Schocket, Sanford M ; Wallace, Mark S</creatorcontrib><description>Neuropathic pain is a common problem in our society affecting nearly 1.5% of the US population. There currently are five medications approved by the US Food and Drug Administration (FDA) for the treatment of neuropathic pain, which include gabapentin, pregabalin, duloxetine, 5% lidocaine patch, and carbamazepine. Other agents with proven efficacy in multiple randomized, placebo-controlled trials include opioids, tricyclic antidepressants, venlafaxine, and tramadol. All of these agents, both FDA-approved and off-label, have been recommended as first-line treatments for neuropathic pain. This article discusses these agents in detail as they relate to the treatment of neuropathic pain.</description><identifier>ISSN: 1531-3433</identifier><identifier>EISSN: 1534-3081</identifier><identifier>DOI: 10.1007/s11916-006-0044-9</identifier><identifier>PMID: 18778572</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Antidepressants ; Central Nervous System Agents - therapeutic use ; FDA approval ; Humans ; Neuralgia - drug therapy ; Pain ; Practice Guidelines as Topic</subject><ispartof>Current pain and headache reports, 2006-06, Vol.10 (3), p.185-190</ispartof><rights>Current Science Inc 2006.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c267t-8b858f16f5587e257547d858aa2c2fba2eb1e0544bc3ca4199bad003abb4a5753</citedby><cites>FETCH-LOGICAL-c267t-8b858f16f5587e257547d858aa2c2fba2eb1e0544bc3ca4199bad003abb4a5753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18778572$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dobecki, Douglas A</creatorcontrib><creatorcontrib>Schocket, Sanford M</creatorcontrib><creatorcontrib>Wallace, Mark S</creatorcontrib><title>Update on pharmacotherapy guidelines for the treatment of neuropathic pain</title><title>Current pain and headache reports</title><addtitle>Curr Pain Headache Rep</addtitle><description>Neuropathic pain is a common problem in our society affecting nearly 1.5% of the US population. There currently are five medications approved by the US Food and Drug Administration (FDA) for the treatment of neuropathic pain, which include gabapentin, pregabalin, duloxetine, 5% lidocaine patch, and carbamazepine. Other agents with proven efficacy in multiple randomized, placebo-controlled trials include opioids, tricyclic antidepressants, venlafaxine, and tramadol. All of these agents, both FDA-approved and off-label, have been recommended as first-line treatments for neuropathic pain. This article discusses these agents in detail as they relate to the treatment of neuropathic pain.</description><subject>Antidepressants</subject><subject>Central Nervous System Agents - therapeutic use</subject><subject>FDA approval</subject><subject>Humans</subject><subject>Neuralgia - drug therapy</subject><subject>Pain</subject><subject>Practice Guidelines as Topic</subject><issn>1531-3433</issn><issn>1534-3081</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkE1LxDAQhoMo7rr6A7xIQPBWzVeb9CiLnyx4cc9hkqZul7apSXrYf2_XXRA8DDO8PDMMD0LXlNxTQuRDpLSkRUbIvoTIyhM0pzkXGSeKnv7ONOOC8xm6iHFLCCNK0XM0o0pKlUs2R-_roYLksO_xsIHQgfVp4wIMO_w1NpVrm95FXPuApxin4CB1rk_Y17h3Y_ADpE1j8QBNf4nOamijuzr2BVo_P30uX7PVx8vb8nGVWVbIlCmjclXTos5zJR3LZS5kNUUAzLLaAHOGOpILYSy3IGhZGqgI4WCMgInmC3R3uDsE_z26mHTXROvaFnrnx6gLJYiQTE3g7T9w68fQT79pJkghRFFSMVH0QNngYwyu1kNoOgg7TYnea9YHzXrSrPeadTnt3Bwvj6Zz1d_G0Sv_ARapd_Q</recordid><startdate>200606</startdate><enddate>200606</enddate><creator>Dobecki, Douglas A</creator><creator>Schocket, Sanford M</creator><creator>Wallace, Mark S</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200606</creationdate><title>Update on pharmacotherapy guidelines for the treatment of neuropathic pain</title><author>Dobecki, Douglas A ; Schocket, Sanford M ; Wallace, Mark S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c267t-8b858f16f5587e257547d858aa2c2fba2eb1e0544bc3ca4199bad003abb4a5753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antidepressants</topic><topic>Central Nervous System Agents - therapeutic use</topic><topic>FDA approval</topic><topic>Humans</topic><topic>Neuralgia - drug therapy</topic><topic>Pain</topic><topic>Practice Guidelines as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dobecki, Douglas A</creatorcontrib><creatorcontrib>Schocket, Sanford M</creatorcontrib><creatorcontrib>Wallace, Mark S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Current pain and headache reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dobecki, Douglas A</au><au>Schocket, Sanford M</au><au>Wallace, Mark S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Update on pharmacotherapy guidelines for the treatment of neuropathic pain</atitle><jtitle>Current pain and headache reports</jtitle><addtitle>Curr Pain Headache Rep</addtitle><date>2006-06</date><risdate>2006</risdate><volume>10</volume><issue>3</issue><spage>185</spage><epage>190</epage><pages>185-190</pages><issn>1531-3433</issn><eissn>1534-3081</eissn><abstract>Neuropathic pain is a common problem in our society affecting nearly 1.5% of the US population. There currently are five medications approved by the US Food and Drug Administration (FDA) for the treatment of neuropathic pain, which include gabapentin, pregabalin, duloxetine, 5% lidocaine patch, and carbamazepine. Other agents with proven efficacy in multiple randomized, placebo-controlled trials include opioids, tricyclic antidepressants, venlafaxine, and tramadol. All of these agents, both FDA-approved and off-label, have been recommended as first-line treatments for neuropathic pain. This article discusses these agents in detail as they relate to the treatment of neuropathic pain.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>18778572</pmid><doi>10.1007/s11916-006-0044-9</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1531-3433 |
| ispartof | Current pain and headache reports, 2006-06, Vol.10 (3), p.185-190 |
| issn | 1531-3433 1534-3081 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68404728 |
| source | MEDLINE; 2022 ECC(Springer) |
| subjects | Antidepressants Central Nervous System Agents - therapeutic use FDA approval Humans Neuralgia - drug therapy Pain Practice Guidelines as Topic |
| title | Update on pharmacotherapy guidelines for the treatment of neuropathic pain |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T15%3A21%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Update%20on%20pharmacotherapy%20guidelines%20for%20the%20treatment%20of%20neuropathic%20pain&rft.jtitle=Current%20pain%20and%20headache%20reports&rft.au=Dobecki,%20Douglas%20A&rft.date=2006-06&rft.volume=10&rft.issue=3&rft.spage=185&rft.epage=190&rft.pages=185-190&rft.issn=1531-3433&rft.eissn=1534-3081&rft_id=info:doi/10.1007/s11916-006-0044-9&rft_dat=%3Cproquest_cross%3E68404728%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2406446914&rft_id=info:pmid/18778572&rfr_iscdi=true |